Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence

Shien,Tadahiko; Tanaka,Takehiro; Tanabe,Masahiko; Okumura,Yasuhiro; Masuda,Norikazu; Yoshida,Atsushi; Arima,Nobuyuki; Komoike,Yoshifumi; Tanaka,Satoru; Iwase,Takuji; Taguchi,Tetsuya; Nakatsukasa,Katsuhiko; Inaji,Hideo; Ishitobi,Makoto

doi:10.3892/ol.2016.5538

Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence

Authors:
- Tadahiko Shien
- Takehiro Tanaka
- Masahiko Tanabe
- Yasuhiro Okumura
- Norikazu Masuda
- Atsushi Yoshida
- Nobuyuki Arima
- Yoshifumi Komoike
- Satoru Tanaka
- Takuji Iwase
- Tetsuya Taguchi
- Katsuhiko Nakatsukasa
- Hideo Inaji
- Makoto Ishitobi
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Pathology, Okayama University Hospital, Okayama 700‑8558, Japan, Division of Breast Oncology, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862‑8505, Japan, Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka 540‑0006, Japan, Department of Breast Surgery, St. Luke's International Hospital, Tokyo 104‑8560, Japan, Department of Breast Oncology, Department of Pathology, Kumamoto Shinto General Hospital, Kumamoto 862‑8655, Japan, Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537‑8511, Japan, Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka 569‑8686, Japan, Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto 602‑0841, Japan
Published online on: December 27, 2016 https://doi.org/10.3892/ol.2016.5538
Pages: 1071-1077
Copyright: © Shien et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aldehyde dehydrogenase 1 (ALDH1) is a cancer stem cell (CSC) marker that is easily evaluable. The expression and clinical significance of ALDH1 in ipsilateral breast tumor recurrence (IBTR) has yet to be investigated. In the present study, the expression profile of ALDH1 and its correlation with prognosis in IBTR tissues was examined. Patients with IBTR from eight institutions were retrospectively enrolled in the study. Immunohistochemistry was used to examine ALDH1 expression patterns in the tissue specimens of primary cancers and IBTRs. ALDH1 expression levels were investigated in 182 IBTR tumors, which included cases of invasive carcinoma selected from 271 consecutive patients with IBTR. ALDH1 was expressed in 23% of the IBTR tissue samples. The rate of concordant expression between primary cancer and IBTR tissues was 68%. There was no significant association between disease‑free survival (DFS) and ALDH1 expression levels in IBTR. IBTRs that expressed ALDH1 and Ki‑67 had a poorer prognosis and this expression pattern was significantly associated with DFS (P=0.0073). The percentages of ALDH1 positive expression in each tissue subtype were as follows: Luminal A, 20%; luminal B, 24%; human epidermal growth factor 2 (HER2), 35%; triple‑negative, 21%. There was a significant correlation between DFS and ALDH1 expression levels in HER2‑type IBTR tissue specimens (P=0.034). In conclusion, it is possible that ALDH1 and Ki‑67 expression levels may be useful for predicting prognosis in patients with HER2-type tumors.

View Figures

View References

1	van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K and Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst. 92:1143–1150. 2000. View Article : Google Scholar : PubMed/NCBI
2	Morris AD, Morris RD, Wilson JF, White J, Steinberg S, Okunieff P, Arriagada R, Lê MG, Blichert-Toft M and van Dongen JA: Breast-conserving therapy vs mastectomy in early-stage breast cancer: A meta-analysis of 10-year survival. Cancer J Sci Am. 3:6–12. 1997.PubMed/NCBI
3	Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 366:2087–2106. 2005. View Article : Google Scholar : PubMed/NCBI
4	Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 347:1227–1232. 2002. View Article : Google Scholar : PubMed/NCBI
5	Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ishitobi M, Okumura Y, Arima N, Yoshida A, Nakatsukasa K, Iwase T, Shien T, Masuda N, Tanaka S, Tanabe M, et al: Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. Ann Surg Oncol. 20:1886–1892. 2013. View Article : Google Scholar : PubMed/NCBI
7	Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Tanaka S, Arima N, Komoike Y, et al: Change in estrogen receptor, HER2 and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. Eur J Surg Oncol. 41:548–552. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wicha MS, Liu S and Dontu G: Cancer stem cells: An old idea-a paradigm shift. Cancer Res. 66:1883–1890, 1895–1896. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ginestier C, Hur MH, CharafeJauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
10	Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Nakano M, Tashima R and Toyozumi Y: The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. J Clin Pathol. 69:255–259. 2016. View Article : Google Scholar : PubMed/NCBI
11	Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Nakano M, Tashima R and Toyozumi Y: A comparison of the hot spot and the average cancer cell counting methods and the optimal cutoff point of the Ki-67 index for luminal type breast cancer. Oncology. 90:43–50. 2016. View Article : Google Scholar : PubMed/NCBI
12	Nogami T, Shien T, Tanaka T, Nishiyama K, Mizoo T, Iwamto T, Ikeda H, Taira N, Doihara H and Miyoshi S: Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases. Breast Cancer. 21:58–65. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ito M, Shien T, Omori M, Mizoo T, Iwamoto T, Nogami T, Motoki T, Taira N, Doihara H and Miyoshi S: Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor. Breast Cancer. 23:437–444. 2016. View Article : Google Scholar : PubMed/NCBI
14	Nogami T, Shien T, Tanaka T, Doihara H, Taira N, Takabatake D, Nishimura R, Nishiyama K, Mizoo T and Ohsumi S: The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells. Breast Cancer. 21:698–702. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K and Arnaout A: Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Cancer Metastasis Rev. 35:427–437. 2016. View Article : Google Scholar : PubMed/NCBI
16	Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G and Barone C: Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous Axillary metastases or recurrent metastatic disease. Clin Breast Cancer. 15:307–312. 2015. View Article : Google Scholar : PubMed/NCBI
17	Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, et al: Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 77:162–167. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241. 2009. View Article : Google Scholar : PubMed/NCBI
19	Benson JR and Rovere GQ della: Ipsilateral breast cancer recurrence. Breast. 17:12–18. 2008. View Article : Google Scholar : PubMed/NCBI
20	Chen SL and Martinez SR: The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. Am J Surg. 196:495–499. 2008. View Article : Google Scholar : PubMed/NCBI
21	McGrath S, Antonucci J, Goldstein N, Wallace M, Mitchell C, Grills I, Jolly S, Kestin L and Vicini F: Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: A molecular based clonality evaluation. Am J Clin Oncol. 33:17–22. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhong Y, Lin Y, Shen S, Zhou Y, Mao F, Guan J and Sun Q: Expression of ALDH1 in breast invasive ductal carcinoma: An independent predictor of early tumor relapse. Cancer Cell Int. 13:602013. View Article : Google Scholar : PubMed/NCBI
23	Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y and Tanimoto A: Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology. 59:776–780. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhou L, Li K, Luo Y, Tian L, Wang M, Li C and Huang Q: Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol. 44:2180–2187. 2013. View Article : Google Scholar : PubMed/NCBI
25	Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V and D'Amico R: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 18:CD0062432012.